“The LINX™ Reflux Management System demonstrated remarkable efficacy at alleviating symptoms of gastroesophageal reflux disease in patients with Barrett’s esophagus,” said Dr. John C. Lipham^‡, General Surgery, Gastrointestinal Surgery, Foregut Surgery at Keck Medicine of USC, Study Investigator on the paper supporting this label update. “With the opportunity to extend this treatment option to more patients with GERD, I am thrilled for patients to experience much-needed relief from this condition and experience improved quality of life.”

It is estimated that 20 percent of adults in the U.S. suffer from GERD, which is a risk factor for BE, a condition in which tissue similar to the lining of the intestine replaces the lining in the esophagus.^2,3 Millions of patients rely on medications that control or suppress acid production in the stomach to treat GERD. However, these medications do not address the mechanical cause of GERD, which is a weak lower esophageal sphincter (LES) muscle. LINX™, a flexible ring of small magnets placed around the LES to help prevent acid reflux, has demonstrated success in treating GERD in patients with and without BE. A single-arm clinical trial (NCT00776997) showed 71 percent of patients with BE who were experiencing GERD symptoms were free from dependence on daily reflux medication after LINX.¹